



2 December 2022

ASX Code: MXC

LSE Code: MXC

MDPI publish peer reviewed academic paper on MGC Pharma research collaboration on cytotoxic effects of Cannabidiol and Cannabigerol on Glioblastoma stem cells

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has had a peer reviewed academic paper entitled '*The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling*' published by MDPI.

MDPI is the largest open access publisher of peer reviewed academic journals, publishing nearly 400 open access journals and the fifth largest publisher overall in terms of journal paper output. The article has been published as a Molecular Cancer Biology research paper.

The glioblastoma research in the publication is a collaboration between MGC Pharma and the National Institute of Biology, a leading research university in Slovenia¹.

The research paper tests Cannabidiol (**CBD**) and Cannabigerol (**CBG**) extracts provided by MGC Pharmaceuticals, and their impact on Glioblastoma cells. The study finds that GPR55 and TRPV1 receptors are the best targets for the antagonistic cannabinoids CBD and CBG (in an optimised mixture) to eliminate Glioblastoma (**GBM**) stem cells.

This approach avoids using psychoactive tetrahydrocannabinol (THC), which is potentially harmful, particularly in older GBM patients, and should be further tested in animal experiments and clinical trials.

Glioblastoma is a fast growing and aggressive form of cancer, usually starting in the brain. Currently only 5-10% of glioblastoma patients live beyond five years following diagnosis².

The article is open access and can be accessed at the following URL:

<https://www.mdpi.com/2072-6694/14/23/5918/pdf>

--Ends--

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.eu

UK Financial and Corporate Advisor

Hannam & Partners

Rupert Fane / Nilesh Patel

+44 7810 056 104

rf@hannam.partners / nilesh@hannam.partners

UK PR Advisors

Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.eu

UK Broker

Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

¹ Refer ASX announcement on 16 June 2022 titled "Successful Glioblastoma Pre-clinical Trial Results"

² <https://www.mdanderson.org/cancerwise/10-year-glioblastoma-brain-tumor-survivor--get-busy-living.h00-159303045.html>



About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    